<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02229071</url>
  </required_header>
  <id_info>
    <org_study_id>ZGDH1B</org_study_id>
    <nct_id>NCT02229071</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma</brief_title>
  <official_title>Donafenib in Advanced Hepatocellular Carcinoma: A Randomized Phase 1B Study of Safety, Efficacy, and Pharmacokinetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tigermed Consulting Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase IB study of donafenib, an oral multikinase inhibitor that targets Raf kinase and
      receptor tyrosine kinases, is to assess toxicity,efficacy and pharmacokinetics in patients
      wiht advanced hepatocellular carcinoma (HCC) .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligibility Criteria:

        -  18 -70 years old;

        -  Patients with measurable, histologically proven, inoperable HCC;

        -  Child-Pugh (CP) score of A;

        -  Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less.

        -  Patients received prior systemic treatments for HCC before 4 weeks;

        -  Patients received operate before 3 months;

        -  Patients received TACE before 4 weeks;

        -  Life expectancy at least 3 months;

        -  Adequate hepatic and renal function;

        -  Adequate hematologic function (platelet count,≥70×109per liter;hemoglobin ≥8.5 g per
           deciliter);

        -  Prothrombin time international normalized ratio≤2; or prothrombin time ≤16 seconds;or
           APTT≤43s;or TT≤21s.

      Exclusion Criteria:

        -  Patients had prior treatment with sorafenib;

        -  CNS involvement.

      Method:

        -  open-label,randomized,multiceters study;

        -  2 dose cohorts: 200mg bid and 300mg bid;

        -  Patients with advanced HCC(inoperable) and Child-Pugh (CP) A , randomized,receive
           continuous donafenib either 200mg bid or 300mg bid in 4 weeks cycles;

        -  Sample size:106 patients(53 patients in each dose cohort).

      Endpoints:

        -  Safety: toxicities are assessed according to CTCAE 3.0;

        -  TTP:Tumor response is assessed every two cycles using RECISIT1.1 criteria;

        -  Donafenib pharmacokinetics is measured in plasma samples.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">October 30, 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>1 years</time_frame>
    <description>Patient visits are scheduled every 4 weeks to monitor safety and drug accountability. Patients were monitored for adverse events by use of the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression(TTP)</measure>
    <time_frame>1 year</time_frame>
    <description>Patient visits are scheduled every 8 weeks to monitor efficacy.TTP is measured from the date of randomisation until disease progression according to RECIST 1.1.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to symptomatic progression(TTSP)</measure>
    <time_frame>1 year</time_frame>
    <description>Symtomatic progression is measured with the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-HP) domain of physical wellbeing and additional concerns at baseline and every 4 weeks.TTSP is measured from the date of randomisation until symptomatic progression.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>HCC</condition>
  <arm_group>
    <arm_group_label>Donafenib(200mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donafenib 200 mg orally twice daily,each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Donafenib(300mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Donafenib 300 mg orally twice daily,each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donafenib(200mg)</intervention_name>
    <description>Donafenib 200mg,bid,po</description>
    <arm_group_label>Donafenib(200mg)</arm_group_label>
    <other_name>A Group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donafenib(300mg)</intervention_name>
    <description>Donafenib 300mg,bid,po</description>
    <arm_group_label>Donafenib(300mg)</arm_group_label>
    <other_name>B Group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 -70 years old

          -  Patients with measurable, histologically proven, inoperable HCC

          -  Child-Pugh (CP) score of A

          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less.

          -  Patients received prior systemic treatments for HCC before 4 weeks

          -  Patients received operate before 3 months

          -  Patients received TACE before 4 weeks

          -  Life expectancy at least 3 months

          -  Adequate hepatic and renal function

          -  Adequate hematologic function (platelet count,≥70×109per liter;hemoglobin ≥8.5 g per
             deciliter)

          -  Prothrombin time international normalized ratio≤2; or prothrombin time ≤16 seconds;or
             APTT≤43s;or TT≤21s.

        Exclusion Criteria:

          -  Patients had prior treatment with sorafenib

          -  CNS involvement.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feng Bi, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sichuan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West China Hospital,SCU</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2014</study_first_submitted>
  <study_first_submitted_qc>August 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2014</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Donafenib</keyword>
  <keyword>HCC</keyword>
  <keyword>Advanced</keyword>
  <keyword>inoperable</keyword>
  <keyword>Phase 1B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

